2021 年 38 巻 5 号 p. 736-739
Evidence is being generated and new treatments are being developed in various neuropathies. This paper discusses about recent progresses that clinicians should be aware of : In Guillain–Barré syndrome, a randomized controlled trial failed to show the efficacy of a second administration of immunoglobulin. Development of new therapies to inhibit complement activation is underway. European Association of Neurological Societies/Peripheral Nerve Society published updated guidelines of CIDP. Clinical subtypes have been organized and subcutaneous immunoglobulin has been added as a recommended treatment. For POEMS syndrome, thalidomide was approved after an investigator–led clinical trial. Moreover, ELISA kit for vascular endotherial growth factor was also approved for diagnosis and evaluation of therapeutic response. ATTRv amyloidosis is an autosomal dominant inherited disorder for which innovative treatments have been implemented. Although ATTRv amyloidosis is rare, it should be kept in mind as a differential diagnosis to provide patients with appropriate treatment as early as possible.
